Chapter 33: Osteoporosis – Drug Management & Prevention

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

If you're here, you're looking for that clinical edge, that shortcut, and today we are doing a really surgical deep dive into Chapter 33.

We're tackling the pharmacotherapeutics of osteoporosis.

Yeah, and it's more than just, you know, weak bones.

It's a progressive systemic issue.

Absolutely.

Managing it means getting comfortable with some pretty different drug classes.

That's a perfect way to put it.

Osteoporosis, fundamentally, it's decreased bone mass, right?

And the actual structure, the microarchitecture inside the bone, it deteriorates.

Which leads straight to fragility and fractures.

Exactly.

And the scale is, well, it's huge.

We're talking about 54 million Americans aged 50 plus.

Wow.

And the stat that always jumps out from the chapter is that 80 % are women,

mostly due to postmenopausal changes.

That's type one.

Right, type one.

But we can't forget type two, the senile type, hitting older men and women, or type three, which is secondary to other conditions, or crucially, medications.

We definitely need to look beyond just postmenopausal women.

Identify those other high risk folks.

Absolutely.

So our mission today, we're going straight from that cellular imbalance, that bone remodeling problem, into the drugs.

Okay.

We'll cover the basic biology quickly, then really hit the dosing details, the quirks, the warnings, especially for those newer bone building agents.

Let's do it.

Right.

Part one, pathophysiology.

So bones always changing, this remodeling cycle.

It's like a construction site, right?

Pretty much.

You've got your osteoblasts or the builders making new bone, and then you have osteoclasts, the demolition crew, breaking down old bone.

And osteoporosis happens when demolition gets ahead of construction.

That's the imbalance.

Resorption outpaces formation, and that spongy trabecular bone, it takes the hit first, it's more metabolically active.

Which brings us to that key molecular system, rank, rank, LOL, OPG.

It sounds complex, but it's central.

It really is, because several major drugs target this exact system.

Think about type I, postmenopausal, osteoporosis, estrogen drops.

Right.

So arene -KL, which basically tells osteoclasts, go, go, go, gets upregulated.

And OPG, the molecule that normally puts the brakes on arene -KL,

that gets suppressed.

So the demolition crew goes into overdrive.

Precisely.

More osteoclasts, faster resorption.

It accelerates things quite dramatically.

Understanding that signaling is key.

Okay.

Risk factors.

We know the big ones.

Age, female sex, Asian or white race, low body weight,

but what about those secondary risks?

The red flags.

Yeah.

Besides conditions like diabetes or hyperthyroidism, you have to look at medications.

It's critical.

Like steroids.

Exactly.

Long -term glucocorticoids are a big one.

Specifically, if someone's on five milligrams or more of prednisone daily for over three months, that's a major flag.

In others, the chapter mentions anticonvulsants, PPIs, even SSRIs.

Yep.

Certain drugs in those classes too.

If you spot those on a med list, you need to be thinking about screening potentially sooner rather than later.

Okay.

Which leads us perfectly into part two.

Diagnosis, the DCASA scan, dual energy x -ray absorbed geometry.

That's the gold standard.

It is.

And it gives us two important numbers, the T score and the Z score.

How do we interpret those?

So the T score compares the patient's bone density, their BMD, to a healthy young adult.

That's the key one for diagnosis.

If that T score is minus 2 .5 or lower,

that's osteoporosis.

Okay.

Minus 2 .5 or less.

And the Z score?

The Z score compares them to people their own age, sex, and ethnicity.

It's often more helpful for, say, premenopausal women or younger men where you wouldn't expect significant bone loss yet.

Got it.

So T score drives the diagnosis.

Now, who needs screening?

The guidelines seem pretty clear.

They are.

All women 65 and up, all men 70 and up.

Plus, younger folks, if they've already had a fragility fracture or have those risk factors we mentioned, like long -term steroid use.

And we have to talk about the FRAX tool.

Oh, absolutely.

The Fracture Risk Assessment Tool.

You can't really make informed treatment decisions without it, especially for people with osteopenia.

Osteopenia being that T score between minus 1 .0 and minus 2 .5.

Exactly.

FRAX is this computer algorithm.

It takes various risk factors and calculates the 10 -year probability of a major osteoporotic fracture or specifically a hip fracture.

And those probabilities guide treatment.

Yes.

If someone has osteopenia but their 10 -year hip fracture risk is 3 % or higher, or their major fracture risk is 20 % or higher, the guidelines say treat them.

Okay.

Crucial tool.

Now, before we get into the actual drugs, the foundation, calcium and vitamin D.

Non -negotiable.

You simply can't build effective therapy on a deficient foundation.

So how much do people need?

For calcium, most adults need about a thousand milligrams a day.

But for women over 50 and men over 70, that bumps up to 1200 milligrams daily.

And there's a key point about taking it.

Something about absorption.

Yes.

Absorption is saturable.

Your body can only absorb so much calcium at once, around 500 to 600 milligrams.

Meaning you have to split up larger doses.

You absolutely do.

If someone needs 1200 milligrams, they should take 600 milligrams twice a day.

Not all at once.

And the type matters too, right?

Carbonate versus citrate.

Big difference in administration.

Calcium carbonate, it's got more elemental calcium, about 40%.

But it needs stomach acid to be absorbed well.

So take it with meals.

Correct.

Calcium citrate, on the other hand, only has about 21 % elemental calcium.

But its absorption isn't acid dependent.

Meaning you can take it any time, even if you're on a PPI.

Exactly.

Much more flexible, especially for patients on acid suppressing meds.

Get that wrong.

And you compromise the foundation.

Okay.

And vitamin D.

For adults over 50, the National Osteoporosis Foundation recommends 800 to 1000 international units, or IU, daily.

What if someone's actually deficient, like their blood level is low?

If their 25 hydroxy vitamin D level is below 30 nanograms per milliliter, that's deficiency.

You need a high dose replacement first.

Something like 50 ,000 IU once a week for maybe 8 to 12 weeks, then start the daily maintenance dose.

Got it.

Replenish first, then maintain.

All right, let's move into the drugs.

Part three, the pharmacological arsenal.

So we start treatment if there's a prior fracture, or the T -score is making 2 .5 or lower, or if they have osteopenia, plus that high FRAX score.

Those are the main triggers from NOF.

And broadly, we have two strategies.

The anti -resortive slowing down bone breakdown.

Right.

And the anabolic is actually stimulating new bone formation.

Let's start with the workhorses, the most common first -line agents.

The bisphosphonates,

elendronate, rhizodronate, zoledronic acid.

Yep, these are the heavy hitters.

They work by inhibiting those osteoclasts, slowing down bone resorption.

They actually get incorporated into the bone matrix.

And they can improve BMD quite a bit.

Yeah, typically 5 to 10 percent increase over two or three years.

They're effective and usually the first choice.

But the administration for the oral ones,

it's notoriously tricky.

What are the absolute must -know rules?

Okay, three critical things for oral bisphosphamates like elendronate or zoledronic acid.

One, take it first thing in the morning on an empty stomach.

Okay.

Two, take it with a full glass, like eight ounces of plain water only.

No coffee, no juice, nothing else.

Plain water.

Got it.

Three, and this is crucial for safety, stay upright, sitting or standing for at least 30 minutes after taking it.

For ibondronate, which is sometimes dosed monthly, it's 60 minutes.

Why stay upright?

To prevent it from refluxing and causing severe esophageal irritation or ulceration.

It's a serious risk if not taken correctly.

Oh, and rule number four, really.

Wait at least 30 minutes, sometimes longer, depending on the specific drug, before eating, drinking anything else, or taking any other medications, especially calcium or antacids.

Right, because absorption is terrible anyway, and other things interfere.

Extremely poor absorption.

You need to give it time alone.

Separate calcium, iron, and antacids by at least two hours.

It's a clinical mind field if patients don't get these instructions right.

Beyond the immediate GI risks, there are longer -term concerns too, right?

ONJ and atypical fractures.

Correct.

Osteonecrosis of the jaw, ONJ, is a rare but serious risk, particularly with IV bisphosphonates or higher doses used in cancer, but it can happen with oral therapy too.

And atypical femur fractures, these unusual breaks in the thigh bone, are linked to long -term use, say, beyond five years.

Which is why we sometimes consider drug holidays.

Exactly.

For lower -risk patients, after about five years of oral therapy or three years of IV zoledronic acid, you might pause the drug and reassess later.

Also, a key contraindication, poor kidney function.

Generally, avoid them if the creatinine clearance is less than 30 or 35 mile element, depending on the agent.

Okay, lots to consider with bisphosphonates.

What about other anti -resorptives?

Riloxafine, the CERN?

Riloxamin is interesting.

It acts like estrogen on bone, reducing resorption, primarily protecting against vertebral fractures.

Plus, it reduces invasive breast cancer risk.

But there's a major downside.

Yes, a black box warning for increased risk of blood clots, DBT, PE, and also stroke.

So you need to weigh that risk, and patients need to stop at 72 hours before any planned immobilization, like surgery or long travel.

Okay, and calcitonin.

It's directly inhibits osteoclasts.

It's less potent than bisphosphonates, often used if others aren't tolerated.

But there's a warning about a possible increased risk of malignancy with long -term use, which has limited its place in therapy.

All right, let's switch gears to the anabolics.

The bone builders, these are for more severe cases.

Generally, yes, for patients at very high fracture risk or those who continue to fracture despite being on an anti -resorptive or can't tolerate them.

First up, the PTH analogs, terapeurotide and abalapurotide.

Right.

So interestingly, continuous high levels of parathyroid hormone actually break down bone.

But giving these analogs as a once daily subcutaneous injection does the opposite.

It stimulates the builders?

It preferentially stimulates the osteoblasts.

So you get rapid new bone formation, increased bone mass.

It's quite effective.

What's the big safety flag here?

The chapter mentions osteosarcoma.

Yeah, that came from studies in rats that showed an increased risk of bone cancer, osteosarcoma.

Because of that, they're contraindicated in people with Paget's disease of bone, prior radiation therapy to the skeleton, or unexplained high alkaline phosphatase levels.

Use is typically limited to about two years lifetime.

And there's another really critical point about stopping them.

This is vital.

When you stop a PTH analog, the bone density gains can be lost very quickly within a year even.

Wow.

So you build it up, then it just disappears.

Unless you follow it immediately with an anti -resortive agent, usually a bisphosphonate to lock in those games.

You absolutely cannot just stop the anabolic therapy without a transition plan that needs serious patient education and follow up.

Okay.

Critical transition needed.

Now, the newest agent in the chapter, Romozozumab,

the sclerostin inhibitor.

Romozozumab, yes.

It's a monoclonal antibody.

It works by inhibiting sclerostin, a protein that normally puts the brakes on bone formation.

So inhibiting the inhibitor boosts formation.

Exactly.

But it also seems to decrease resorption slightly.

So it has this unique dual effect.

Increases formation, A and D, decreases breakdown.

It's very potent.

How's it given?

It's a subcutaneous injection, 210 milligrams given once a month, but only for a total of 12 months.

Treatment shouldn't go beyond one year.

And like the others, it comes with a significant warning,

perhaps the most serious one.

It does.

It has a major black box warning regarding increased risk of cardiovascular events,

heart attack,

MI, stroke, and cardiovascular death.

That sounds really concerning.

How do you use a drug like this?

Very carefully.

You absolutely cannot start it in anyone who's had an MI or stroke within the last year.

You have to weigh that potent dual mechanism against the significant CV risk, especially in older patients who often have underlying heart disease.

It really limits who is an appropriate candidate.

And like PTH analogs, you need to transition to an anti -resorptive after the 12 months are up.

Another tricky transition.

Okay.

One more agent to cover, kind of bridging the categories.

Dinozumab, the rank -legged inhibitor.

It's listed as anti -resorptive.

Correct.

Dinozumab is also a monoclonal antibody, but it targets rank ligand itself, remember rankEL, the go -go -go signal for osteoclasts?

Yeah.

Dinozumab blocks it, so it prevents osteoclasts from forming, functioning, and surviving.

Very effectively shuts down bone resorption.

I was dosed.

It's quite convenient for patients, actually.

A 60 -milligram subcutaneous injection given just once every six months, usually administered in a clinic or doctor's office.

Okay.

But it shares a potential problem with the anabolics.

Right.

Something about stopping it.

Yes.

This is a huge point.

Just like the PTH analogs, if you stop Dinozumab abruptly or even miss a dose significantly, you can get rapid bone loss.

Bone density can plummet, and there's a rebound increase in fracture risk.

So same issue.

You need a plan for what comes next if you stop it.

Absolutely.

You need to transition to another agent, often a bisphosphonate, to maintain the density gained with Dinozumab.

It's not a drug you can just stop casually.

That rapid rebound effect is a must -know.

Wow.

Okay.

Lots of options, lots of nuances.

Let's try to pull this together in part four with a clinical scenario.

The chapter has case study 2, patient AK.

He's a 65 -year -old white male, has rheumatoid arthritis, smokes, and importantly, he's on chronic steroids, 10 -milligram prednisone daily.

His T -score is NIA 2 .0.

Okay.

So T -score of NIA 2 .0 is technically osteopenia, not osteoporosis.

Right.

So does he need drug therapy?

Yes, absolutely.

This highlights a critical point.

Don't just look at the T -score in isolation.

His long -term, relatively high -dose steroid use is a major secondary cause of bone loss.

That factor alone pushes him into the high -risk category, according to the NOF guidelines, justifying treatment even with just osteopenia.

Makes sense.

The chapter suggests rhizadrinate and oral bisphosphonate as a good starting point, along with calcium and vitamin D, of course.

That's a standard first -line approach, but if AK couldn't tolerate the oral bisphosphonate, maybe GI issues or difficulty with administration rules, what are the alternatives?

Well, the chapter suggests the 5 -saladronic acid once a year, or Dinosumab injections every six months could be options.

Good.

And if we do start rhizadrinate, what's the essential patient education for AK, especially considering he's probably on other meds for his RA?

We'd have to really drill down on those administration rules.

Take it first thing alone, with only plain water.

Stay upright for the full 30 minutes, and critically, wait at least two hours before his calcium or any of his other morning RA meds.

Yeah, messing that up means it won't work, and he risks esophageal problems.

Adherence and correct administration are everything with oral bisphosphonates.

Okay, finally monitoring.

We start the drug, check in with the patient on side effects and adherence every three to six months.

When do we recheck the DEXA scan?

Typically, rotate the DEXA every two years after starting therapy.

And is there a specific site that shows changes best?

Yes, the chapter points out that the lumbar spine BMD is often the most sensitive indicator of response to therapy.

Trebecular bone, which is plentiful in the spine, turns over faster, so you'll usually see the positive effects of an anti -resorptive drug there first within that two year time frame.

You hope to see that five to ten percent increase.

That's a great clinical pearl.

Okay, what a journey through this therapeutic landscape.

We went from basic bone biology, RNKL and OPG, all the way to these complex monoclonals with dual actions and serious warnings.

It really covers a lot.

I think the key takeaway is it starts with the foundation, maximizing calcium and vitamin D.

Then you assess risk using the T -score in FRIX.

Then you choose your strategy.

Slow down breakdown with anti -resorptives like bisphosphonates or for high risk patients build new bone with anabolic.

Always mindful of the specific risks and needs.

And maybe connecting it bigger picture.

Drugs are powerful, yes, but we can't forget things like fall prevention.

For these high risk patients, preventing falls is just as critical because a fracture means the therapy, in a sense, has failed.

Yeah, that's a great point.

Okay, here's a final provocative thought for you, the listener, based on the chapter.

No osteoporosis drug therapy is meant to be indefinite.

Especially after years of use, treatment needs to be reassessed annually.

The idea of drug holidays, switching therapies, it's an ongoing management process.

Definitely not set it and forget it.

So this deep dive gave you hopefully a streamlined overview of osteoporosis pharmacotherapy based strictly on chapter 33.

We really hope this helps your learning and makes this complex topic stick.

Thank you for being a part of our little last minute lecture family.

Until next time.